503 — Lansen Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall Cap

Market Cap
HK$750.60m
Enterprise Value
HK$527.08m
Revenue
$65.56m

Annual income statement for Lansen Pharmaceutical Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	C2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	56.9	54.3	54.4	54.2	65.6
Cost of Revenue
Gross Profit	30.3	33.3	35.2	34.4	44.3
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Operating Interest Expense / Income
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	53.6	32.6	3.32	52.6	53.1
Operating Profit	3.27	21.6	51.1	1.54	12.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2.09	18.6	91.4	2.4	9.91
Provision for Income Taxes
Net Income After Taxes	0.16	18.3	88.2	0.903	8.6
Net Income Before Extraordinary Items
Net Income	0.16	18.3	88.2	0.903	8.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	0.16	18.3	88.2	0.903	8.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.003	0.006	0.116	0.009	0.024
Dividends per Share
Special Dividends per Share